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Report of the 3rd Havemayer workshop on allergic diseases of
the horse, Hólar, Iceland, June 2007
Abstract
Allergic diseases occur in most mammals, although some species such as humans, dogs and horses seem
to be more prone to develop allergies than others. In horses, insect bite hypersensitivity (IBH), an
allergic dermatitis caused by bites of midges, and recurrent airway obstruction (RAO), a hyperreactivity
to stable born dust and allergens, are the two most prevalent allergic diseases. Allergic diseases involve
the interaction of three major factors: (i) genetic constitution, (ii) exposure to allergens, and (iii) a
dysregulation of the immune response determined by (i) and (ii). However, other environmental factors
such as infectious diseases, contact with endotoxin and degree of infestation with endoparasites have
been shown to influence the prevalence of allergic diseases in humans. How these factors may impact
upon allergic disease in the horse is unknown at this time. The 3rd workshop on Allergic Diseases of the
Horse, with major sponsorship from the Havemeyer Foundation, was held in Hólar, Iceland, in June
2007 and focussed on immunological and genetic aspects of IBH and RAO. This particular venue was
chosen because of the prevalence of IBH in exported Icelandic horses. The incidence of IBH is
significantly different between Icelandic horses born in Europe or North America and those born in
Iceland and exported as adults. Although the genetic factors and allergens are the same, exported adult
horses show a greater incidence of IBH. This suggests that environmental or epigenetic factors may
contribute to this response. This report summarizes the present state of knowledge and summarizes
important issues discussed at the workshop.
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Allergic diseases occur in most mammals, although some species such as humans, dogs and 54 
horses seem to be more prone to develop allergies than others. In horses, insect bite 55 
hypersensitivity (IBH), an allergic dermatitis caused by bites of midges, and recurrent airway 56 
obstruction (RAO), a hyperreactivity to stable born dust and allergens, are the two most 57 
prevalent allergic diseases.  58 
Allergic diseases involve the interaction of three major factors: (i) genetic constitution, (ii) 59 
exposure to allergens, and (iii) a dysregulation of the immune response determined by (i) and 60 
(ii). However, other environmental factors such as infectious diseases, contact with endotoxin 61 
and degree of infestation with endoparasites have been shown to influence the prevalence of 62 
allergic diseases in humans.  How these factors may impact upon allergic disease in the horse 63 
is unknown at this time. The 3rd workshop on Allergic Diseases of the Horse, with major 64 
sponsorship from the Havemeyer Foundation, was held in Holar, Iceland, in June 2007 and 65 
focussed on immunological and genetic aspects of IBH and RAO.  66 
This particular venue was chosen because of the prevalence of IBH in exported Icelandic 67 
horses.  The incidence of IBH is significantly different between Icelandic horses born in 68 
Europe or North America and those born in Iceland and exported as adults. Although the 69 
genetic factors and allergens are the same, exported adult horses show a greater incidence of 70 
IBH. This suggests that environmental or epigenetic factors may contribute to this response. 71 
This report summarizes the present state of knowledge and summarizes important issues 72 




1. Introduction 75 
The 3rd Havemeyer workshop focussed on immunological and genetic aspects of insect bite 76 
hypersensitivity (IBH) and recurrent airway obstruction (RAO).  77 
 IBH, or sweet itch, is a recurrent pruritic allergic dermatitis of the horse occurring in summer 78 
and caused by IgE-mediated reactions to bites of midges. The allergens causing IBH are likely 79 
salivary gland proteins from these insects, but the individual allergens have not yet been 80 
identified. IBH occurs in horses of various breeds worldwide, except for regions, like Iceland, 81 
where Culicoides midges are absent. However, IBH has an especially high prevalence in 82 
horses of the Icelandic breed exported from Iceland to geographic areas where Culicoides spp. 83 
are present. IBH causes considerable discomfort to the affected horses, which scratch 84 
excessively especially in the mane and tail regions, causing secondary skin lesions. Presently, 85 
no long term effective treatment exists. 86 
RAO or heaves, is a severe, potentially debilitating, inflammatory airway disease typically 87 
affecting middle-aged horses and resulting in coughing, increased respiratory effort and 88 
exercise intolerance due to bronchospasm and mucus accumulation in the airways. RAO, 89 
caused in part by inherited factors and influenced by environmental conditions, is common in 90 
stabled horses fed hay. It is initiated by the inhalation of organic dust and, once sensitised, a 91 
horse becomes hypersensitive to airborne particles and requires careful management. 92 
However, the relative importance of IgE-mediated reactions, Th1- and Th2-type profiles, 93 
innate immunity, and individual cytokines is still unclear. 94 
This summary report presents the results of a workshop held at Holar, Iceland in June 2007. 95 
Advances in immunology, such as the detection of new pathways by microarray technology, 96 
as well as progress in the identification, cloning and delivery of recombinant allergens were 97 
presented. In genetics, the completion of the horse genome sequence and the development of 98 
new genetic tools for the horse, open new avenues for the study of both diseases. Extensive 99 
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sampling of RAO and IBH-affected horses is ongoing. Presentations and state-of-the-art 100 
lectures also addressed new reagents and technologies for the study of these diseases and new 101 
therapeutic concepts. Summary statements presented by working groups formed at the 102 
meeting and plenary discussions identified important questions to be addressed, potential 103 




2. Immunopathology of RAO and IBH and immune response of foals 106 
RAO (heaves) 107 
In conventional indoor stable environments with hay feeding and straw bedding, the air in the 108 
breathing zone of horses contains very high levels of organic dust with allergens and non-109 
specific irritants like endotoxin (Woods et al., 1993). Since the use of various terms referring 110 
to environment-induced lower airway disease has led to confusion, consistent working 111 
definitions were proposed based on the state-of-the-art of our knowledge (Robinson, 2001): 112 
RAO, according to these definitions, is a severe, debilitating disease characterized by 113 
coughing and increased breathing effort due to cholinergic bronchospasm and airway 114 
hyperreactivity as well as neutrophil and mucus accumulation in the airways believed to result 115 
from  hypersensitivity reactions to various inhaled allergens. Removal of hay and straw often 116 
leads to remission of the disease. While its phenotype is defined, the immunopathophysiology 117 
of heaves remains ill understood. 118 
In the last decade, a number of studies have addressed the role of T cells in equine diseases. 119 
There are now examples of predominant Th1 (e.g. Herpesvirus; Slater et al., 2006) and Th2 120 
(e.g. parasite defense) type responses in the horse, supportive for the basic concept of the Th1 121 
vs. Th2 paradigm in horses (Horohov, KY, USA). 122 
To date, there are reports of a predominant Th2-type response in RAO and Summer pasture 123 
associated (SPA-) RAO with increased numbers of interleukin (IL)-4 and IL-5 secreting (in 124 
situ hybridization) cells and increased mRNA levels of IL-4 and IL-13 in BAL of RAO and 125 
SPARAO horses (Lavoie et al., 2001; Beadle et al., 2002; Cordeau et al., 2004). However, 126 
there are also reports of either a Th1-type profile (Ainsworth et al., 2003), or studies 127 
suggesting no involvement of either type responses in heaves (Kleiber et al., 2005). Th1-type 128 
cytokines, such as interferon (IFN)-γ, can also be increased in crisis and may persist longer 129 
during remission. Furthermore, non-specific responses to endotoxin, alone and through 130 
8 
 
potentiation of reactions to mould allergens, play a role in RAO (Pirie et al., 2003) and 131 
endotoxin increases Toll-like receptor (TLR)-4 and TLR2 mRNA in horse lungs (Singh et al., 132 
2006). It was proposed that some contradictory results could in part be due to investigations 133 
of different groups of RAO-affected horses at different time-points in the course of the 134 
disease (Horohov, KY, USA). Information presented at the workshop supports the 135 
involvement of a Th2-type response in RAO, and also showed the potential of microarray 136 
expression technology for the identification of new candidate genes. 137 
IL-8, a potent chemokine for neutrophils, was shown to be increased in BALF (Franchini et 138 
al., 2000) and the epithelium (Ainsworth et al., 2006) of RAO-affected horses. Based on 139 
reports that IL-17 is increased in stabled RAO-affected horses (Debrue et al., 2005) and on 140 
findings in other species, Ainsworth/Wagner (NY, USA) hypothesized that mononuclear cell 141 
derived IL-17 and IL-23 may drive epithelial chemokine production in RAO. They found, 142 
however, that neutrophil-depleted BAL cells of horses with heaves and controls showed a 143 
similar inherent expression of IL-17, IL-23, IL-8 and IL-1β as well as a similar increase of 144 
these cytokines after treatment with LPS, β-glucan and hay dust extracts. These results 145 
suggest that production of these cytokines by mononuclear cells plays a minimal role in the 146 
propagation of airway neutrophilia in RAO. Evidence presented by Lavoie (Montreal, 147 
Canada) showed that IL-4, a major Th2-type cytokine, has the potential to contribute to 148 
neutrophil activation: recombinant equine IL-4 causes morphological changes in blood 149 
neutrophils, increases IL-8 mRNA levels and potentiates effects of LPS and TNF-α on IL-8 150 
expression by pulmonary artery endothelial cells. Receptors for IL-4 (IL-4R), however, were 151 
not increased on neutrophils of RAO-affected compared to healthy horses. This does, 152 
however, not exclude an involvement of the IL-4R in the pathogenesis of RAO, as Gerber 153 
(Bern, Switzerland) presented evidence for a genetic linkage of polymorphisms in IL-4R-α 154 
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with RAO and increased expression of this receptor in one high-prevalence family of horses 155 
but not in another one (see below).  156 
A model of ovalbumin (OVA) sensitized horses, which develop airway obstruction and 157 
neutrophilia and a Th2-type profile was presented (Horohov, KY, USA). These results are 158 
consistent with the development of Th2-type response in horses exhibiting some of the main 159 
characteristics of RAO. As in other species, the effectiveness of parasite defence in the horse 160 
relies on a Th2-type response, specifically the production of IL-4, IL-5 and IL-13 cytokines. 161 
In this model, acute parasitism (infection with Strongylus vulgaris) in parasite-free horses 162 
exacerbated the allergic response to OVA inhalation. A similar effect of parasitism on allergy 163 
development has been proposed in humans (Carvalho et al., 2006). 164 
Gene microarrays, developed for human gene expression studies, have helped identify new 165 
candidate genes involved in both innate and adaptive immunity. These new candidate genes 166 
may also play a role in RAO (Ramery et al., 2008; Ramery, Liège, Belgium). Differential 167 
expression of the genes PTX3, CYBB, MARCKS was confirmed with real time RT-PCR. 168 
There is evidence from other species that PTX3 overexpression can contribute to lung injury 169 
and the down regulation of CYBB to the recruitment of neutrophils. The importance of these 170 
mediators in the initiation and expression of RAO remains to be determined. 171 
The following consensus statement on RAO immunology for future research was made 172 
(Lavoie, Canada; Horohov, USA; Ramery, Belgium; Wilson, UK; Gerber, Switzerland):  173 
1. While the RAO phenotype has been clinically well-defined, no accepted 174 
recommendations exist for standardized exposure protocols and sampling times in 175 
experimental studies of RAO. This, and the as yet ill-defined overlying variation from 176 
chronicity and age-related changes, make comparisons between studies difficult. 177 
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2. A further methodological issue is to define which tissue is best to study: 178 
bronchoalveolar lavage (BAL) fluid; BAL separated cells; bronchial brushings or lung 179 
tissue biopsies. 180 
3. The role of IgE and individual allergens in RAO is still unclear. An experimental 181 
protocol for the definitive investigation of this question would need to: 182 
a. Identify potential major recombinant allergens in RAO-affected individuals by 183 
serological screening and confirm the relevance of putative recombinant 184 
allergens by functional in vitro tests for each affected individual.  185 
b. Perform regional bronchial challenge with the identified recombinant allergens 186 
and measure reaction by BAL transfer containing allergen-specific IgE to a 187 
naïve unaffected individual.  188 
c. Perform regional bronchial challenge and compare reaction before and after 189 
transfer. 190 
4. Exposure experiments in neutrophil-depleted RAO-affected horses are needed to 191 
determine the relevance and pathophysiological contribution of neutrophils in RAO. 192 
5. Longitudinal, epidemiological studies are necessary to identify predisposing factors in 193 
the environment of foals and young horses that may influence the development to RAO. 194 
 195 
Insect bite hypersensitivity (IBH) 196 
Compared to RAO, the pathogenesis of IBH is better characterised. Various studies have 197 
suggested that IBH is an IgE-mediated reaction to bites of insects, mainly Culicoides species 198 
but other insects have been implicated in some cases. Affected horses most often show 199 
immediate type reactions after intradermal injections of Culicoides extract and sometimes also 200 
react to extracts from other insects. In a subset of horses, delayed type reactions have been 201 
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observed following intradermal tests with insect extracts. Peripheral blood leukocytes of IBH 202 
affected horses release significantly more sulfidoleukotriene or histamine after stimulation 203 
with Culicoides and to some extent also with Simulium extract than those of control horses 204 
(Baselgia et al., 2006). Sera of IBH affected horses also have significantly more often IgE and 205 
IgG abs binding to Culicoides salivary proteins (Wilson et al., 2001; Hellberg et al., 2006). 206 
A modified Prausnitz-Küstner experiment has provided the first direct evidence that IgE 207 
mediates classical Type-I allergy in horses and plays a major role in the pathogenesis of IBH 208 
(Wagner, NY, USA): IgE antibodies were purified with anti-IgE affinity columns from serum 209 
of IBH-affected horses. These purified IgE abs were injected intradermally in four clinically 210 
healthy horses. The following day, Culicoides allergen extract was injected at the same sites. 211 
Skin reactions were not observed in response to allergen alone, and in two horses after 212 
stimulation at any previous IgE injection site. However, the other two healthy horses showed 213 
an immediate skin reaction at the previous injection sites of IgE obtained from allergic horses 214 
(Wagner et al., 2006). These findings support an early study showing that regain-like 215 
antibodies can be transferred in the horse (Matthews et al., 1983). 216 
In the skin, IBH lesions are characterised by oedema, infiltration with eosinophils, increased 217 
numbers of IgE-bearing cells, mast cells (van der Haegen et al., 2001), and increased 218 
expression of Th2 cytokines (Marti, Berne, Switzerland). Chronic lesions are characterised by 219 
hyperkeratosis and T cell infiltrates. There is presently no evidence of increased expression of 220 
Th1 cytokines (IFN-γ) in chronic IBH-lesions as known in human atopic eczema. However 221 
further studies are necessary to confirm these findings as only a small number of chronic 222 
lesions were tested so far (Marti, Berne, Switzerland).  223 
In contrast to human atopic eczema, clinically normal skin of horses affected with IBH is not 224 
characterized by increased levels of IL-1β mRNA. Intradermal injection of C. nubeculosus 225 
extract stimulates local IL-1β transcription in all horses independent from disease status, but 226 
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the extent of upregulation from basal levels only reaches statistical significance in IBH-227 
affected horses during the active stages of the disease. In humans and mice, IL-1 RA down-228 
regulates antigen specific IL-4 and IgE responses with concomitant enhancement of IFN-229 
γ production in vitro and in vivo. There is no indication so far that cutaneous IL-1RA has a 230 
modulatory effect in equine IBH (Kolm-Stark et al., 2006). 231 
In summary, an IgE-mediated mast cell degranulation, i.e. a type I hypersensitivity reaction is 232 
sufficient to explain the acute phases of IBH. This, however, does not exclude that other 233 
immunological mechanisms are also involved in chronic stages of the disease.  234 
A special focus was then given to the specific aspects of IBH in Icelandic horses. IBH is a 235 
serious problem in exported Icelandic horses but also occurs in Icelandic horses born abroad. 236 
The disease is not seen in the native horse population because the causative agents, Culicoides 237 
spp., are not present in Iceland. As introduction Björnsdottir (Holar, Iceland) summarised a 238 
recently published study on the prevalence of IBH in Icelandic horses (Björnsdottir et al., 239 
2006). Overall, IBH was diagnosed in 34.5% of 330 horses exported from Iceland to 240 
Denmark, Sweden or Germany. The number of affected horses increased with duration of 241 
exposure to midges. At two years post export, the prevalence was 49.5%, and even reached 242 
54% in horses that had lived in areas heavily infested by Culicoides spp. A slightly lower 243 
prevalence of IBH of 47% was found in another group of 191 horses exported to Norway or 244 
Sweden that had been living in Culicoides spp. rich environments for at least two years. Age 245 
at export, gender, sire and country of examination were not associated with the prevalence of 246 
IBH in exported Icelandic horses. Information about the time of onset of the disease was 247 
available for 49 horses and ranged from 1 to 8 years after export. Most commonly the first 248 
signs of IBH were detected 2 to 3 years after export (mean 2.4 year). By comparison, only 249 
4.6% of 1192 Icelandic horses born in Germany in Culicoides infested areas were affected 250 
with IBH. It was concluded that Icelandic horses are predisposed to IBH most likely as a 251 
13 
 
result of a lack of exposure to Culicoides bites in early life and possibly because of the great 252 
environmental changes following export. The Icelandic horse does not seem to be inherently 253 
more susceptible to IBH than other breeds if the individuals are born in an environment where 254 
midges are present. 255 
Hamza (Berne, Switzerland) compared the Th1/Th2 polarity in healthy and IBH-affected 256 
horses of the Icelandic breed imported from Iceland to Europe (1st generation horses) or born 257 
in Europe (2nd generation horses). During summer, after in vitro stimulation, PBMC from 258 
IBH- affected horses produced significantly more IL-4 and less IFN-γ than those of healthy 259 
horses (Hamza et al., 2007). Most interestingly, upon polyclonal or antigen-specific 260 
stimulation, lymphocytes of 1st generation Icelandic horses expressed significantly higher 261 
levels of Th2-cytokines than those of 2nd generation Icelandic horses matched with regard to 262 
disease state. This may indicate that Th2-type cytokine expression is suppressed in horses 263 
born in Switzerland. These results raise the question whether the IL-4 response in 2nd 264 
generation horses is suppressed by regulatory cytokines. To test this hypothesis, supernatant 265 
from PBMC cultures of healthy 2nd generation horses were added to cultures of IBH-affected 266 
1st generation horses. Addition of these supernatants led to a significant decrease of IL-4 267 
production by PBMC of IBH 1st generation horses. This effect could be mimicked by addition 268 
of IL-10 and TGFβ1. On the other hand, neutralisation of IL-10 and TGFβ1 in PBMC 269 
cultures of healthy 2nd generation horses led to a significant increase of IL-4 production 270 
(Hamza et al., 2008). These findings indicate that in 1st generation horses the immune 271 
response is Th2 biased and that this could be due to decreased regulatory cytokine expression 272 
(Hamza, Berne, Switzerland). Further studies are necessary to investigate the presence of 273 
regulatory T cells in the horse and their potential role in allergic disease. 274 
The discussion then focussed on factors which may lead to this Th2 biased immune response 275 
which results in a high prevalence of IBH in imported Icelandic horses. The timing of 276 
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exposure to Culicoides bites was considered to be a major factor: horses born in Europe are 277 
first exposed to Culicoides allergens at the age of 2-3 months when their own IgE production 278 
is low and maternal IgE levels are present although decreasing (Wilson, Bristol, UK). There is 279 
presently no evidence supporting priming by maternal IgE (Wilson, Bristol, UK; Wagner, 280 
NY, USA) and whether maternal factors such as passive IgG antibody transfer have a 281 
protective effect remains unknown. Horses imported from Iceland are usually imported as 282 
adults i.e. the first contact with the Culicoides allergens happens with a mature immune 283 
system. However, besides age at first exposure to Culicoides allergens other environmental 284 
factors may also contribute to the high prevalence of IBH in imported horses. A recent study 285 
had shown that horses living in Iceland have high total IgE levels, which decreased some time 286 
after import to Switzerland and remained relatively low in horses remaining unaffected by 287 
IBH, while IgE levels increased again in horses developing IBH (Wilson et al., 2006). As 288 
high total IgE levels are induced by helminth infections, it was thus hypothesized that horses 289 
living in Iceland (where anthelminthic use is infrequent) may have a higher endoparasitic 290 
burden then horses living in Europe. It has been previously shown that horses imported from 291 
Iceland to Norway have a lower incidence of IBH if they arrive during the summer compared 292 
to the winter (Halldorsdottir et al., 1991). Taking this observation together with the results 293 
reported here we propose that horses exposed to Culicoides immediately after import would 294 
have a high level of total IgE (presumably to helminths) which may block the Fcε receptors 295 
on mast cell, thus competitively preventing a new IgE response to Culicoides. In contrast, 296 
total IgE levels of horses imported in winter will have dropped until the following spring and 297 
sensitization of mast cell by exposure to Culicoides at this time may be facilitated. 298 
Infestation with helminths also influences the immune response at the Th-level, leading to a 299 
strong Th2 response. A pilot study, however, showed that there is no evidence for high IL-4 300 
production following polyclonal activation or stimulation of PBMCs with helminth extracts in 301 
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horses living in Iceland (Hamza, Berne, Switzerland). Studies in humans, however, have 302 
shown that chronic infections with endoparasites lead a strong regulatory network (Carvalho 303 
et al., 2006). Regulatory cytokines need now to be determined in these horses. Further 304 
environmental factors specific for the Iceland environment are also the absence of some viral 305 
infections such as equine influenza and EHV1 and 4 (Svansson, Reykjavik, Iceland). Viral 306 
diseases are known to induce a Th1-type immune response, inhibiting a Th2 response. This 307 
inhibition loop may thus be absent in horses living in Iceland favoring a higher Th2 response 308 
in exported horses exposed to insect bites in the new environment.  309 
Post export, Icelandic horses are usually immediately de-wormed and vaccinated, and 310 
depending on the season of export, exposed to Culicoides bites. It was agreed that studies are 311 
needed to investigate whether Culicoides bite exposure alone or other environmental factors 312 
are involved in the high prevalence of IBH in horses exported from Iceland to Europe. 313 
In summary, while the pathogenesis of IBH is relatively well-defined and clearly related to 314 
Th2-type, IgE-mediated reactions, the pathogenesis of RAO is less clear. Different Th-type 315 
immune responses are probably involved in the pathogenesis of RAO depending on time 316 
point, exposure to antigens and airway irritants and also depending on the genetic background 317 
of the horse. 318 
Foals 319 
As the differences in the immune response between foals and adult horses may be one of the 320 
factors contributing to the differences in IBH prevalence in horses exposed for the first time to 321 
bites of Culicoides as adults (i.e. horses imported from Iceland to Europe) as compared to 322 
foals born in an environment where IBH allergens are present, data on immune responses in 323 
foals were also presented and discussed at this workshop. 324 
While transfer of IgG occurs in all vertebrates, IgE is not transferred in all mammal species. 325 
Wagner (NY, USA) and Wilson (Bristol, UK) showed that in the horse there is maternal 326 
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transfer of IgE with the colostrums: IgE antibodies detected in foals in the first 3-4 months of 327 
life are of maternal origin and levels are not correlated with those later in life. Furthermore, 328 
there is evidence for IgE binding to mast cells directly after birth. IgE positive intestinal mast 329 
cells are found in the lamina propria of neonatal foals but disappear after a few weeks and re-330 
appear later (Wilson, Bristol, UK). They can be frequently found in lymph nodes (Wagner, 331 
NY, USA). IgE then becomes undetectable for a variable period of time until the foal’s 332 
endogenic production begins at 6-9 months of age. The levels of early endogenic IgE 333 
production at six months of age are correlated with levels later in life at least until three years 334 
of age.  335 
How maternal IgE present in young foals may influence and modulate their immune response 336 
and development is currently unknown. The relatively late onset of endogenous production 337 
and the lack of a correlation between maternal and endogenous levels may explain, however, 338 
why in horses IgE-mediated allergic diseases are usually not observed before puberty. 339 
Further characterisation of foals’ immune development has come from the study on cytokine 340 
profiles over time (Horohov, Lexington, KY, USA): IL-13 may be initially elevated in 341 
newborn foals and then declines over time. Further, diminished INF-γ, IL-4, IL-5 and IL-10 342 
production characterizes neonatal foals compared to adult horses. Thus, there is currently no 343 
evidence supporting Th2 biases in foals, and the role of these cytokine profiles and 344 
fluctuations in the onset of allergy is unclear. Low INF-γ both at the mRNA and protein level, 345 
however, may predispose foals to intracellular pathogens like Rhodococcus equi and rotavirus 346 
(Breathnach et al., 2006). 347 
Cunningham (London, UK) than gave an overview of new potential therapeutic targets in 348 
equine allergic diseases, such as inhibition of cytokines and chemokines or inhibition of 349 
transcription factors which should result in decreased synthesis of multiple inflammatory 350 




3. Serology, other in vitro allergy tests and intradermal testing in RAO and IBH 353 
 354 
There is older evidence suggesting IgE-mediated type I hyperreactivity (Halliwell et al., 1993; 355 
Hare et al., 1999) in RAO. Newer studies showed that within the same environment, unrelated 356 
RAO-affected horses have increased serum IgE levels against Aspergillus fumigatus and 357 
Alternaria alternata allergens (Künzle et al., 2007). However, environmental as well as 358 
genetics factors influence mould allergen-specific IgE levels in the horse (Eder et al., 2001; 359 
Curik et al., 2003). In horses living under various environmental conditions there was no 360 
significant difference in serum IgE levels against Alternaria alternata and Aspergillus 361 
fumigatus extracts between RAO-affected and control horses (Eder et al., 2000). Increased 362 
levels in RAO horses were only found for specific IgE against the recombinant allergens rAsp 363 
f 7 and 8 and Alt a 1. Evidence presented at this workshop indicates that total IgE is not 364 
associated with the RAO phenotype (Gerber, Berne, Switzerland). Contrarily, total IgE is 365 
influenced by environmental factors (predominantly parasite loads) and decreases with age 366 
(Marti, Berne, Switzerland). In contrast, allergen specific IgE (rAsp7) and, more strongly, the 367 
IgG subclass IgGa (IgG1) are associated with the RAO-phenotype in two warmblood 368 
halfsibling high-prevalence families. Both IgGa and allergen specific IgE were also higher in 369 
off-spring of one compared to off-spring of another RAO-affected sire.  370 
Overall, commercial allergy tests have not been shown to be useful for the diagnosis of RAO 371 
so far. Comparing a serological IgE ELISA (the FcRIα-based Test; ALLERCEPTTM, Heska), 372 
an in vitro sulfidoleukotriene release assay (Cellular Antigen Stimulation Test (CAST®), DPC 373 
Bühlmann, Switzerland) and intradermal testing (IDT) Marti (Berne, Switzerland) found 374 
some agreement between the tests: the majority of positive reactions in all tests were found 375 
with mite extracts, but none of the tests showed a significant difference between RAO-376 
affected and control horses. In contrast, another commercial serological IgE ELISA test, 377 
showed high sensitivity (92%) and acceptable specificity (76%) in different groups of RAO-378 
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affected and control horses. However, the nature of the reagent in this ELISA was not 379 
disclosed, and therefore the specificity of the IgE detection remains unclear. 380 
Various tests have been evaluated for in vitro diagnosis of IBH recently. They include 381 
serological (FcRIα-based Test (ALLERCEPTTM from Heska) and Polycheck Allergie NF 382 
Horse Panel, BioCheck GmbH, Münster, Germany) as well as functional in vitro tests such as 383 
the Functional In vitro Test (FIT, Hannover), where histamine release is measured, or the 384 
Cellular Antigen Stimulation Test (CAST®, DPC Bühlmann, Switzerland), where released 385 
sulfidoleukotrienes are measured after incubation of peripheral blood leukocytes with 386 
presumptive allergen extracts.  387 
In the first study presented (Kolm-Stark, Vienna, Austria) the FcRIα-based serological test, 388 
the FIT and the CAST® were compared to intradermal testing, using the same five insect 389 
extracts (Tabanus, Simulium, Culex, Stomoxys and Culicoides nubeculosus). Sixteen horses 390 
with and 29 horses without IBH were included in the study. In summary, there was fair to 391 
moderate agreement (kappa statistics) between the three in vitro tests and clinical diagnosis of 392 
IBH.  393 
In the second study (Frey, Norrköping and Uppsala, Sweden) sera from 99 Icelandic horses 394 
were tested in the FcRIα-based Test (ALLERCEPT TM, Heska). IgE levels against five 395 
insect species were determined (Culicoides, Simulium, Tabanus, Stomoxis and Culex). All 396 
horses living in Iceland, with one exception, had IgE levels below the cut off of the test. 397 
Within the group of horses born in Iceland and exported to Sweden, 45% of the IBH-affected 398 
and 35% of the healthy horses gave a positive reaction with at least one insect extract. Within 399 
the horses born in Sweden, the proportion of horses showing a positive reaction with at least 400 
one insect extract was lower both in the IBH-affected group (17%) as well as in the healthy 401 
animals (10%). The results of this study will be presented in more details in Frey et al. (2008). 402 
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A test for determination of allergen specific IgE in horse sera using a monoclonal anti-IgE 403 
antibody, which is presently being developed (Polycheck Allergie NF Horse Panel, BioCheck 404 
GmbH, Münster, Germany), was evaluated (Marti, Berne, Switzerland) for diagnosis of IBH. 405 
For this purpose, sera of 48 IBH-affected and 49 healthy control horses, usually living in the 406 
same environment as the IBH-affected horses, were used. A receiver operator curve (ROC) 407 
analysis was first performed to determine the best cut off of the assay. Using this cut off, the 408 
test with Culicoides nubeculosus extract had a sensitivity of 71% and a specificity of 92%. 409 
Sensitivity and specificity of the test were lower with a Simulium vittatum extract (67% and 410 
69%, respectively) confirming a previous study with the CAST (Baselgia et al 2006). These 411 
findings provide further evidence, together with that fact that Culicoides but not Simulium are 412 
absent in Iceland, that the main allergens for IBH are derived from Culicoides spp.  413 
In conclusion, there was a fair to moderate agreement between the in vitro tests presented here 414 
and the clinical diagnosis of IBH. The performance of these tests needs to be improved and 415 
this can be achieved by the use of high affinity IgE reagents (monoclonal antibodies) and of 416 
pure recombinant allergens instead of the whole body extracts which are presently being used. 417 
For RAO the situation is more complex as it is still controversial if and to which extend IgE-418 
mediated reactions are involved in the pathogenesis of this disease. Further studies are also 419 
needed to identify the specific antigens that are involved in RAO.  420 
 421 
4. Allergens 422 
While no recent data were presented on the allergens that might be responsible for RAO, a 423 
number of studies are now underway to identify the specific allergens causing IBH. Previous 424 
studies had shown that Culicoides whole body extracts contain a wide range of IgE-binding 425 
antigens and that all allergic horses show positive reactions with these antigens (Wilson et al., 426 
2001). In a recent study using Culicoides nubeculosus salivary gland extract (Hellberg et al., 427 
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2006), ten different IgE binding protein bands were identified, with molecular weights 428 
ranging between 75 and 12 kDa. It was shown that serum IgE of most of the allergic horses 429 
bind to at least one salivary gland protein but with variable affinity, and that each horse shows 430 
an individual IgE binding pattern to the different allergens present in the salivary gland 431 
extract (Marti, Berne, Switzerland).  432 
A proteomics approach was used to identify candidate allergens for IBH which is described in 433 
more details in Wilson et al. (2008). In brief, this study showed that Culicoides salivary gland 434 
extract contains a limited number of highly expressed proteins corresponding to abundant 435 
mRNA species and that a group of proteins with basic pI and molecular weights of about 40 436 
kD are the most frequent IgE binding proteins in 2D blots (Wilson, Bristol, UK). 437 
A” candidate allergen” approach was used by Björnsdottir (Reyjkavik, Iceland): Antigen 5 438 
and hyaluronidase are known allergen in bee and vespid venom and EST sequences from C. 439 
sonorensis with homology to antigen 5 and hyaluronidase are available. Based on these 440 
sequences, antigen 5 and hyluronidase have been isolated from a C. nubeculosus salivary 441 
gland library. These are now in the process of being expressed as recombinant proteins. 442 
In summary two different cDNA libraries have been made from C. nubeculosus salivary 443 
glands and cDNA clones encoding putative allergens are available including D7 proteins, 444 
antigen 5, hyluronidase, trypsin as well as various clones with homology to novel C. 445 
sonorensis salivary gland sequences with unknown function (Wilson, Bristol, UK).  In 446 
particular, one additional candidate allergen, a glycoprotein with an observed molecular 447 
weight of about 45-50 kDa and a calculated PI of 9.1 which was similar to the C. sonorensis 448 
salivary protein AY603640 was identified. 449 
Using a different approach, clones expressing IgE-binding proteins from Simulium vittatum 450 
have been isolated using phage surface display technology. Seven putative Simulium vittatum 451 
salivary gland allergens have been cloned and expressed in E. coli, including a protein with 452 
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homology to antigen 5. This protein appears to be an interesting candidate allergen as it binds 453 
significantly more often IgE antibodies from sera of IBH-affected horses than from healthy 454 
control horses (Marti, Berne, Switzerland). Interestingly, antibodies produced against the r- 455 
antigen 5 protein from S. vittatum also bound to a protein band from C. nubeculosus SGE of a 456 
similar molecular weight, suggesting that the antigen 5 protein from S. vittatum and C. 457 
nubeculosus are closely related.  458 
The question to which extent the various Culicoides species contain conserved allergens was 459 
raised at the workshop. Studies have shown that horses with IBH usually showed positive 460 
reactions in intradermal testing with different species of Culicoides and even with Culicoides 461 
species which are not native to the areas where the horses are living (Anderson et al., 1993; 462 
Langner et al., 2008). The fact that most IBH-affected horses show IgE-binding to at least one 463 
salivary gland protein from Culicoides nubeculosus, a species which is only rarely found in 464 
Switzerland seems to confirm these findings (Hellberg et al., 2006). On the other hand, 465 
comparison of cDNA sequences of C. sonorensis EST sequences with sequences generated 466 
from C. nubeculosus sequences suggests that for some sequences, although they share 85% 467 
amino acid homology, this was seldom in stretches long enough to provide an immune 468 
epitope (Wilson, Bristol, UK; Wilson et al., 2008).  469 
In summary, the search of the specific allergens responsible for IBH is progressing. It was 470 
agreed that there is a need to find and express putative recombinant allergens for IBH both in 471 
E. coli and insect cells. These putative recombinant allergens then need to be tested in vitro 472 
and in vivo for their relevance as allergens for IBH. It was also stated that it would be very 473 





5. New treatment of allergy 477 
As IBH is in often due to IgE mediated reactions and the specific IBH allergens are in the 478 
process of being identified, there is good chance to implement a successful allergen-specific 479 
immunotherapy (SIT) for this condition in the future. On the other hand, SIT for treatment of 480 
RAO cannot be presently envisaged due to the lack of knowledge about the molecular 481 
structures involved in the immunopathogenesis of RAO which still need to be identified. 482 
There are no recent studies published on the efficacy of immunotherapy for IBH. However, it 483 
is generally recognised that the success of specific immunotherapy for IBH is currently 484 
limited, probably because of the use of Culicoides whole body extracts instead of pure 485 
salivary gland proteins. In humans, an effective immunotherapy leads to a change in the 486 
Th1/Th2/Treg ratios and the induction of regulatory T cells. A high antigenicity leads to a 487 
Th1 response, which results in a counter regulatory induction of IL10 and Tregs (Larché et al., 488 
2006). However, the immunological changes leading to a successful SIT in humans require a 489 
long time to establish, which strongly compromises the patient’s compliance and, as a 490 
consequence thereof, the number of patients which are choosing SIT as a therapeutic option 491 
for allergy (Crameri, 2007). 492 
Novel approaches for SIT against IBH were discussed at this workshop, including DNA 493 
vaccination, the use of viral vectors or protein vaccination with allergens coupled to modular 494 
antigen translocating (MAT) molecules, which enhance the antigen presentation through 495 
intracellular targeting of the MHC class II presentation pathway (Crameri, Davos 496 
Switzerland; Crameri et al., 2007).  497 
Different pilot studies have been performed with the aim to improve immunotherapy for 498 
equine allergy. As the specific allergens for IBH have not been identified yet, studies aimed at 499 
shifting the balance of the immune response from a Th2 to a Th1 phenotype were performed 500 
using human serum albumin (HSA) as a model allergen. DNA vaccination of horses with 501 
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HSA resulted in a very weak immune response which did not abrogate the IgE response after 502 
boosting with HSA protein in aluminium hydroxide (Svansson, Reykjavik, Iceland). The aim 503 
of the next pilot study was then to improve HSA expression from the vectors with a Kozak 504 
sequence and the cytomegalovirus (CMV) intron A. Insertion of CMV intron A diminished 505 
the expression of HSA from the pcDNA vectors whereas insertion of a Kozak sequence 506 
upstream of the gene increased the in vitro expression both in COS7 cells and primary horse 507 
cells derived from skin, lung, duodenum and kidney (Olafsdottir, Reykjavik, Iceland; 508 
Olafsdottir et al., 2008). The use of adjuvants inducing a Th1 shift is another option for 509 
improvement of specific immunotherapy. Monophosphoryl-lipid (MLP) was tested as an 510 
adjuvant and compared to aluminium hydroxide (alum) in a further pilot study. Horse 511 
immunised with HSA/MLP had a slightly higher IFN-γ/IL-4 ratio than horses immunised with 512 
HSA/aluminium hydroxide. However, both groups responded with similar IgG subclass 513 
profiles. The HSA-specific IgE response was boosted to high levels in the HSA/MLP horses 514 
but was more transient than in the HSA/alum horses that showed a strong and persistent IgE 515 
response (Torsteinsdottir, Reykjavik, Iceland). It was concluded that unlike in laboratory 516 
mice, MLP does probably not induce a sufficiently strong Th1 immune response to induce 517 
Tregs and inhibit a Th2 response in the horse.  518 
The following issues regarding specific immunotherapy (SIT) were discussed (Lunn, CO, 519 
USA; Crameri, Davos, Switzerland; Svansson, Reykjavik, Iceland): If the specific allergens 520 
are used as proteins for SIT their immunogenicity could be improved through coupling to 521 
modular antigen translocating (MAT) molecules (Crameri, Davos, Switzerland). 522 
Alternatively, DNA vaccination could be used. However, although DNA vaccination induces 523 
a Th1 response in the horse it seems to be quite inefficient. This could be improved by 524 
physically targeting the lymph nodes, testing various CpG motifs as adjuvants, and by the 525 
addition of cytokines. Another option could be the use of viral vectors. The immune response 526 
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in viral infections is generally Th1–mediated and could thus induce Tregs. Several groups 527 
have been working with human and animal herpes viruses as a model for potential vectors for 528 
gene delivery. It was shown that the immunological response to EHV-2 is strongly Th1 biased 529 
(Svansson, Reykjavik, Iceland). An EHV-2 vector could thus be engineered as a vector for 530 
vaccination against IBH. The approach to vaccination using EHV-1 as vaccine vector has 531 
recently been described in the horse (Rosas et al., 2007). Alternatively, a commercial non 532 
persistent canary pox vector could be used (Lunn, CO, USA). This vector is presently used for 533 
vaccination against various viral diseases in the horse with good results (Poulet et al., 2006; 534 
Siger et al., 2006). 535 
Finally, it was also discussed that for the Icelandic horses, a preventive immunisation with the 536 
relevant IBH allergens before export to Culicoides infested areas could be a possibility to 537 
reduce the high incidence of IBH in these horses. 538 
 539 
6. Genetics of RAO and IBH 540 
 541 
Antczak (NY, USA) presented recent advances in the understanding and information gained 542 
on the horse genome. Sequencing of the whole equine genome has been completed; this and 543 
other advances offer new tools to identify candidate genes for disease susceptibility. A 544 
concerted international effort has led to the development of tools such as a synteny map, a 545 
genetic linkage map, a cytogenetic map, a radiation hybrid (RH) map, and the on-going effort 546 
to produce a high-resolution BAC-based physical map of the horse genome. To date the 547 
‘Newmarket Horse Genetic Linkage Map’ consists of 950 microsatellite markers covering all 548 
autosomes and the X chromosome (Swinburne et al., 2000; Swinburne et al., 2006). 549 
Furthermore, The National Human Genome Research Institute of the USA has funded and 550 
completed a 7X sequence of the horse genome, with SNP discovery. These tools are now 551 
becoming available to the equine research community. 552 
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A genetic predisposition for RAO has been previously shown in different full- and half sibling 553 
groups (Gerber 1989; Marti et al., 1991). Gerber (Berne, Switzerland) presented the validation 554 
of a new scoring system for larger epidemiological and genetic studies. A standardized 555 
questionnaire was used to gather information on the horses’ history of chronic coughing, 556 
respiratory distress, increased breathing effort after exercise, and nasal discharge, all graded 557 
into categories of frequency and severity of symptoms. This information was used separately 558 
for analyses and compounded into a Horse Owner Assessed Respiratory Signs Index 559 
(HOARSI): healthy (no symptoms observed = HOARSI 1), mildly affected (some nasal 560 
discharge and/or occasional cough =HOARSI 2), moderately affected (frequent coughing 561 
=HOARSI 3), severely affected (moderate to severe coughing and poor performance= 562 
HOARSI 4). Using the HOARSI, a strong heritability for RAO was confirmed in two large 563 
Warmblood half-sibling families of off-spring from RAO-affected sires (Ramseyer et al., 564 
2007). Coughing, compared to increased nasal discharge, poor performance and abnormal 565 
breathing pattern most markedly distinguished genetically predisposed RAO-affected 566 
offspring. Compared to maternal half-siblings, the risk of offspring from affected stallions 567 
was 4 to 5.5 fold increased. From preliminary segregation analyses, the investigators conclude 568 
that a single major gene cannot explain the observed phenotypes. The high heritabilities 569 
suggest the presence of additional major genes.  570 
Association and segregation analysis of markers for epithelial signaling factors and other 571 
microsatellites located near atopy candidate genes as well as gene expression studies indicate 572 
IL4RA as a candidate gene with disease association in one family but not in the other, 573 
indicating possible genotypic locus heterogeneity for this disease (Jost et al., 2007). Results 574 
from a whole genome scan showed association with other chromosomal regions in addition to 575 
the one around IL4RA. Furthermore, preliminary results indicate that offspring from one high 576 
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prevalence family have lower parasitic burden (decreased fecal egg counts) than control 577 
pasture mates (Gerber, Berne, Switzerland). 578 
A genetic basis of IBH has been demonstrated in Swiss Warmbloods and other breeds (Marti 579 
et al., 1992; Lazary et al., 1994). Björnsdottir (Hólar, Iceland) found an overall prevalence of 580 
4.6 % in close to 1200 Icelandic horses born in Germany. When both parents were affected by 581 
IBH the prevalence was significantly higher (12.2 %) compared to offspring with one of the 582 
parents affected (6.5 %) or offspring with two unaffected parents (2.9 %). Interestingly, 583 
disease status of the stallions was significant only when affected stallions were born in 584 
Germany, but not when they had been born in Iceland. Thus, the high prevalence of IBH in 585 
exported Icelandic horses appears to reflect environmental rather than genetic factors. Frey 586 
(Norrköping and Uppsala, Sweden) presented an on-going project in 27 Swedish-born 587 
Icelandic horse half-sib families consisting of 1211 individuals classified by questionnaire 588 
data into healthy, mild, moderate and severe IBH. The main goal of the project is to use 589 
samples from all affected individuals (8.3%) and healthy controls from each family to 590 
perform a whole genome association analysis by genotyping with a SNP chip.  591 
Horin (Brno, Czech Republic) reported that out of 56 breeding mares of the Old Kladruber 592 
breed, which is genetically isolated and inbred, 17 were classified as IBH susceptible 593 
(showing clinical signs of IBH in at least one of nine seasons) and39 as resistant (no clinical 594 
signs of IBH over nine years). A genome scan using 50 microsatellites and 9 single nucleotide 595 
polymorphisms (SNP) in 5 candidate genes identified significant associations between the 596 
microsatellite AHT04 as well as SNPs in the FcεR1 alpha and the IFNγ genes. Furthermore, a 597 
significant difference of total IgE levels was found between IFNγ intron 1 SNP heterozygotes 598 
and homozygotes. 599 
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The following issues were discussed and summarised (Antczak, NY, UK;  Horin, Brno, 600 
Czech Republic; Gerber, Berne, Switzerland; Björnsdottir, Holar, Iceland; Frey, Norrköping 601 
and Uppsala, Sweden): 602 
Both RAO and IBH have a large environmental component and both are probably complex 603 
traits, with more than 2 genes with major effects involved. Overall, there is no breed 604 
specificity for RAO or IBH. However, there is a high incidence of IBH in exported Icelandic 605 
horses, which is probably due to environmental factors (first exposure to allergen as adults). 606 
The fact that only 50% of these imported Icelandic horses become IBH-affected still suggests 607 
that genetic factors may be involved and the question was raised whether it would be possible 608 
to breed out IBH susceptible horses. For RAO, the identification of susceptible animals prior 609 
to developing the condition could allow prevention of the clinical manifestation of the disease 610 
through management such as dust/allergen poor environment and help preventing high risk 611 
matings. Furthermore, identification of genes responsible for RAO susceptibility could 612 
contribute to a better understanding of the pathogenesis of this disease. 613 
For the future, it was recommended to collect samples (DNA bank) from phenotypically well 614 
characterized cases and controls. Furthermore, once candidate genes have been identified it 615 
will be needed to demonstrate that they translate into immunological anomalies. For 616 
functional genomics different samples, i.e. for RNA isolation, will be needed (genotyping 617 
versus expression studies). Samples should also be collected from different breeds. However, 618 
there should be enough samples from each breed to perform an analysis within breed. 619 
Samples can be from unrelated individuals or families. As both RAO and IBH are complex 620 
traits with many genes involved, a larger number of cases and controls will be needed (>100 621 
per group).  622 
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New genomic resources (e.g SNP chips) and bioinformatic approaches will likely become 623 
available within the next three years. They are currently expensive but costs will decrease. As 624 
cheaper alternative small, targeted SNP arrays may be useful for some genetic studies. 625 
 626 
 627 
7. Conclusion 628 
 629 
In conclusion, this workshop has shown that while it is still controversial whether RAO is an 630 
allergic reaction and if so, which are the causative allergens for RAO, there is an improved 631 
understanding of the pathophysiology leading to RAO. The presence of a genetic 632 
predisposition for this condition has been thoroughly documented and the availability of DNA 633 
samples from families of RAO affected sires may allow, in the future, to identify the genes 634 
involved in RAO susceptibility. The genetics approach may also be a way to better understand 635 
the pathogenesis of this disease as shown with the example of the IL-4Rα gene.  636 
The immunopathogenesis of IBH is better characterised. However, the next task will 637 
be to understand which immunological mechanisms lead to the high prevalence of IBH in 638 
horses imported from Iceland to Europe. This may allow identifying a way to prevent IBH in 639 
exported Icelandic horses and contribute to the understanding of the increase of allergy 640 
prevalence in humans. The first priority for research on IBH is now to identify the allergens at 641 
the molecular level. This will open the way to a causative treatment of the disease and to a 642 
better understanding of the immunopathogenesis underlying this allergic condition. Genetic 643 
studies are presently also being performed for IBH. First insights into the immune response of 644 
foals contribute to understand susceptibility of foals to some infectious diseases, such as 645 
Rhodoccocus infections. Additionally, the low levels of serum IgE early in life may explain 646 
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